Your Health, We Care
Release date: 2024-08-13 17:54:31 Recommended: 161
Venetoclax is an oral targeted drug that can effectively inhibit the anti-apoptotic function of BCL-2 protein and restore the normal death of cancer cells. The drug is usually used in combination with other anti-cancer drugs, and patients need to take it under the guidance of a doctor.
For patients with chronic lymphocytic leukemia, venetoclax is dosed as follows: 20 mg daily for week 1, 50 mg daily for week 2, 100 mg daily for week 3, 200 mg daily for week 4, and 400 mg orally daily for patients at week 5 and beyond.
For patients with acute myeloid leukemia (AML), the dose-escalation regimen of venetoclax typically begins on Day 1 of Cycle 1 and lasts for 3 to 4 days. The specific dose is 100 mg daily on day 1, 200 mg daily on day 2, and 400 mg daily on day 3. This escalation regimen helps patients gradually adjust to drug therapy.
According to the results of existing clinical studies, the precautions for venetoclax are summarized as follows:
In trials in patients with relapsed or refractory multiple myeloma, venetoclax in combination with bortezomib and dexamethasone increased mortality; This combination is not recommended except in controlled trials.
Tumor lysis syndrome (TLS), including fatal events and renal failure requiring dialysis, has occurred in patients treated with venetoclax.
There are also some potential adverse reactions during the use of venetoclax. According to clinical trial and label data, at least 20% of patients experienced one or more of the following adverse events:
Thrombocytopenia may cause patients to bleed or ecchymosis easily, and in severe cases, even serious complications such as intracranial hemorrhage. Doctors will keep a close eye on the patient's platelet levels and take measures such as platelet transfusions if necessary, while adjusting the dose of drugs to control symptoms.
Anemia makes patients feel tired, weak, and dizzy, which affects the quality of daily life. Patients with significant symptoms of anemia may need adjuvant therapy such as iron, folic acid, or vitamin B12 in addition to blood transfusion therapy to improve anemia.
[Warm tips] Patients should actively communicate with their doctors about their drug feelings, physical reactions, and changes in their condition; Follow your doctor's medication instructions and take your medication on time and in the right amount.
